Trump promises Schumer funding for NY tunnel project — if Penn Station and Dulles Airport are renamed after him Bad Bunny doesn't get paid for the Super Bowl halftime show—here's why School officials ...

Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and Johnson & Johnson’s rival factor XIa inhibitor in a blockbuster indication.

Patients with large vessel occlusion (LVO) stroke achieved successful angiographic reperfusion after thrombectomy. Results from the CHOICE-2 trial showed that adjunctive intra-arterial (IA) alteplase ...

OCEANIC-STROKE shows asundexian cuts ischemic stroke recurrence by 26% in patients taking standard antiplatelet therapy, with no major bleeding increase. Asundexian is a direct oral inhibitor of FXIa ...

CHOICE2 randomized 400 patients across 14 Spanish centers to thrombectomy alone versus thrombectomy plus intraarterial alteplase, with 90-day mRS as the primary endpoint. Excellent outcomes (mRS 0–1) ...

Findings from OCEANIC-STROKE, including the main results and a prespecified subgroup analysis, will be presented for the first time during two late-breaking sessions at the International Stroke ...

Druckli Tools for Cinema 4D adds new node assets, distributions and generators including Plane Split and 3D Noise.

Boundary Trails Health Centre has acquired a specialized neuro chair for its Rehabilitation Services Department. Funded by ...

Candice Maenza received salary support from a National Institutes of Health grant. Robert Sainburg receives funding from the National Institutes of Health, National Institute of Child Health and ...

For those who have experienced a stroke, the chances of a second one are high. An experimental Bayer drug reduced this risk by 26% in a pivotal trial, supporting the case for this pill as a potential ...

It's a terrible day for gamers who were waiting for Gearbox Software's Borderlands 4 to make its debut on the Nintendo Switch 2 this year: It may no longer be happening. The news comes after publisher ...